HeartBeam Inc. (NASDAQ: BEAT) has launched a pilot study focused on evaluating its proprietary on-demand 12-lead ECG patch for detecting coronary artery disease and ischemia, a condition characterized by inadequate blood flow and oxygen supply to tissue. This announcement marks a significant step in the development of the HeartBeam patch, which has the potential to disrupt the $2 billion long-term continuous monitor and mobile cardiac telemetry (MCT) markets.
Coronary artery disease remains one of the most urgent and widespread health threats worldwide, contributing to millions of deaths each year and often progressing silently until a major cardiac event occurs. As healthcare providers search for faster and more accessible ways to identify high-risk patients earlier, HeartBeam's technology aims to address a critical gap in ambulatory monitoring. According to the company, ischemia detection has not been possible on patch-based ambulatory monitors, and they do not provide clinical-grade insights over an extended period of time.
HeartBeam CEO Robert Eno stated, "Ischemia detection has not been possible on patch-based ambulatory monitors, and they do not provide clinical-grade insights over an extended period of time. The HeartBeam patch is designed to change that. A device capable of generating an on-demand 12-lead ECG has the potential to provide clinicians with a powerful new tool for detecting coronary artery disease and ischemia in an ambulatory setting."
The pilot study represents a critical milestone for HeartBeam as it seeks to validate the clinical utility of its patch. The company believes that a successful study could pave the way for broader adoption of its technology, offering a non-invasive, convenient, and cost-effective alternative to traditional cardiac monitoring methods. By enabling on-demand ECG recordings, the HeartBeam patch could help identify patients at risk of cardiac events earlier, potentially improving outcomes and reducing healthcare costs.
The launch of this study comes at a time when the prevalence of coronary artery disease is intensifying as populations age and cardiovascular risk factors become more common. The global burden of cardiovascular disease underscores the need for innovative diagnostic tools that can be used in outpatient settings. HeartBeam's patch, if proven effective, could fill a significant void in the current monitoring landscape, where existing patch-based systems lack the ability to detect ischemia over extended periods.
For more information about HeartBeam and its latest developments, visit the company's newsroom at https://nnw.fm/BEAT.
